Navigation Links
Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk
Date:3/1/2011

RICHMOND, Va., March 1, 2011 /PRNewswire/ -- Health Diagnostic Laboratory Inc. (HDL, Inc.), www.myhdl.com, announced today its partnership to develop a novel laboratory developed test with Gamma Therapeutics, Inc., an Oregon-based biotechnology venture developing diagnostic test and surgical therapy solutions for the cardiovascular disease industry.

Cardiovascular disease (CVD), coronary heart disease (CHD) and stroke are responsible for 16.7 million, or 29.9% of total global deaths associated with some type of disease, according to the World Health Organization. In 2010, CVD became the leading cause of death in developing countries. At least 20 million people survive heart attacks and strokes every year; many require continuing costly clinical care.

Gamma Therapeutics, launched in November 2010, is bringing to market, in a joint product development effort with HDL, Inc., a novel CVD Risk Assay to enhance cardiologists' ability to assess heart attack and stroke risk by providing a new predictive and prognostic tool. The laboratory developed CVD Risk Assay is based upon a naturally occurring clotting protein in human blood called Gamma Prime Fibrinogen, a biomarker strongly associated with cardiovascular disease. The laboratory-developed test version of the Gamma Therapeutics' CVD Assay will be offered exclusively by HDL, Inc., which also will take the lead in BETA testing of the assay for FDA approval.

The Gamma Therapeutics' executive management team includes David H. Farrell, Ph.D., Founder and CSO and David F. Eastman, M.Sc., CEO. Its science advisory board is comprised of leading scientists in cardiovascular disease, pathology and hematology research, with expertise in CVD patient medicine and preventative care, cardiovascular surgery, heart attack and stroke risk assessment, clinical and diagnostic testing, surgery-based treatment and business experience in growing biotechnology and medical device ventures.

The launch of the partnership between HDL, Inc. and Gamma Therapeutics represents a combined effort to advance the preventative model for chronic disease management, based on a recent monumental shift in the way physicians test for life-threatening conditions. Moving beyond traditional lipid testing, HDL. Inc. is a market leader in providing comprehensive diagnostics capable of detecting risk factors predisposing patients to cardiovascular disease earlier than ever before possible.  

"The results are simple," said Tonya Mallory, CEO and Co-Founder of Virginia-headquartered HDL, Inc. "Thanks to advanced testing, it's now possible to reveal risk factors and biomarkers for cardiovascular and related diseases. The partnership with Gamma Therapeutics demonstrates HDL, Inc.'s ongoing goal to provide best of breed biomarkers, such as this new assay." Using a systematic approach to identify factors contributing to disease allows HDL, Inc. to provide its physicians with a better basis for effective treatment plans.

About HDL, Inc.

Health Diagnostic Laboratory Inc. (HDL, Inc.), a CAP accredited leader in health management, offers a comprehensive test menu of risk factors and biomarkers for cardiovascular and related diseases. Our systematic approach identifies factors contributing to disease and provides a basis for effective personalized treatment, allowing physicians to more effectively manage patients.  As an added value, patients receive a personalized overview of their risk factors along with intensive counseling from expert Health Coaches at no additional cost, improving compliance and enhancing potential outcomes. For more information, www.myhdl.com.

About Gamma Therapeutics, Inc.

Gamma Therapeutics, Inc., is an Oregon biotechnology venture developing a novel class of diagnostic test and surgical therapy solutions for the cardiovascular disease industry.  All of its products are based upon a natural protein in blood called Gamma Prime Fibrinogen. Patent-pending and patented products under development include the GammaCoeur™ CVD Risk Assay, GammaSeal™ Surgical Incision Sealant and Gammarin™ Anti-Coagulant Blood Thinner. Gamma Therapeutics' corporate offices and laboratory are headquartered at 2611 SW Third Avenue, Suite 280N, Portland, Oregon 97201. For more information, www.gamma-therapeutics.com.


'/>"/>
SOURCE Health Diagnostic Laboratory, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Tone Deafness Explained, from the Harvard Health Letter
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
8. ViroPharma to Present at Three Upcoming Healthcare Conferences
9. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
10. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):